Meiji to Develop Lineup Unaffected by Price Revisions, Bolster Earnings from New Drugs/Generics in Focus Areas

July 12, 2023
Meiji Seika Pharma President Daikichiro Kobayashi Meiji Group is looking to establish a portfolio that would not be influenced by price revisions, such as antibiotics and vaccines, while also reinforcing its profits through innovative medicines and generics for infectious and...read more